Healthscope's NZ pathology outperforms on Wellington lab deal

Healthscope's NZ pathology outperforms on Wellington lab deal
Paul McBeth
By Paul McBeth Feb. 23 (BusinessDesk) - ASX-listed Healthscope's New Zealand pathology business outperformed the rest of the group after its successful bid to provide lab services across the Wellington region drove a 21 percent gain in revenue.  The New Zealand unit increased operating earnings before interest, tax, depreciation and amortisation 17 percent to A$23.2 million in the six months ended Dec. 31, as revenue climbed to A$106 million from A$88 million a year earlier, the Melbourne-based company said in a statement. That outperform...